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Abstract
Cerebral vasospasm is a major cause of morbidity and mortality in patients with subarachnoid hemorrhage (SAH),
causing delayed neurological deficits in as many as one third of cases. Existing therapy targets induction of cerebral
vasodilation through use of various drugs and mechanical means, with a range of observed efficacy. Here, we
perform a literature review supporting our hypothesis that transcranially delivered ultrasound may have the
ability to induce therapeutic cerebral vasodilation and, thus, may one day be used therapeutically in the context
of SAH. Prior studies demonstrate that ultrasound can induce vasodilation in both normal and vasoconstricted
blood vessels in peripheral tissues, leading to reduced ischemia and cell damage. Among the proposed mechanisms is
alteration of several nitric oxide (NO) pathways, where NO is a known vasodilator. While in vivo studies do not point to
a specific physical mechanism, results of in vitro studies favor cavitation induction by ultrasound, where the
associated shear stresses likely induce NO production. Two papers discussed the effects of ultrasound on the
cerebral vasculature. One study applied clinical transcranial Doppler ultrasound to a rodent complete middle cerebral
artery occlusion model and found reduced infarct size. A second involved the application of pulsed ultrasound in vitro
to murine brain endothelial cells and showed production of a variety of vasodilatory chemicals, including by-products
of arachidonic acid metabolism. In sum, nine reviewed studies demonstrated evidence of either cerebrovascular
dilation or elaboration of vasodilatory compounds. Of particular interest, all of the reviewed studies used
ultrasound capable of transcranial application: pulsed ultrasound, with carrier frequencies ranging between 0.5
and 2.0 MHz, and intensities not substantially above FDA-approved intensity values. We close by discussing
potential specific treatment paradigms of SAH and other cerebral ischemic disorders based on MRI-guided
transcranial ultrasound.
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Background
Aneurysmal subarachnoid hemorrhage is a devastating
neurological condition with an estimated incidence of
7–9 per 100,000 person-years [1]. Roughly, one fifth of
patients do not survive the initial bleed, and those who do
remain at substantial risk for further morbidity and mor-
tality. Overall death rates for subarachnoid hemorrhage
range from 32 to 67 %, and 60 % of those who survive
suffer from long-term disabilities, including cognitive
difficulties, psychiatric illness, impaired activities of
daily living, and inability to return to work [2].
In 20 to 40 % of patients, new ischemic neurological
deficits that were not present on hospital admission be-
come apparent in the days and weeks following the ictus
[3]. Such delayed neurological deficits (DNDs) can be
mild or severe, focal or non-focal, and reversible or per-
manent. Lethal infarctions occur in 7 % of cases [3].
Review
The pathophysiology of vasospasm: large vessels
Classically, these phenomena have been ascribed to
spasm of large cerebral arteries leading to ischemia in
downstream tissue, and a substantial body of evidence
has been published in support of this conclusion [4–7].
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For example, an early study by Fisher and colleagues
demonstrated that DND occurred only in patients with
severe vasospasm, and these deficits could frequently be
attributed to a lesion in the brain region supplied by the
spastic vessels [7].
Recently, however, there has been growing recogni-
tion that large-vessel spasm alone is not a sufficient ex-
planation [8, 9]. For instance, angiographic narrowing
of large-caliber vessels is evident in roughly two thirds
of patients, but only one third actually exhibit symp-
toms [3]. Moreover, DNDs can occur in patients with-
out large-vessel spasm [10, 11], and when vasospasm
and a DND are present in the same patient, the clinical
picture cannot always be attributed to a lesion in the
region supplied by the affected vessel [8, 11]. Indeed, as
many as one third of patients suffer infarctions in terri-
tories that could not be predicted by angiography [12].
Finally, there are conflicting reports on whether or not
angiographic spasm and elevated blood velocity measured
by transcranial Doppler (TCD) ultrasound—a measure-
ment frequently used as a proxy for radiographic evidence
of spasm—are ultimately associated with worse clinical
outcome [13–15].
The pathophysiology of vasospasm: cerebral
microvasculature
In support of the idea that major-vessel vasospasm alone
is not sufficient, there is a substantial body of evidence
indicating that the cerebral microvasculature plays an
important role. Post-mortem studies of subarachnoid
hemorrhage (SAH) patients have demonstrated ischemic
lesions that are much more frequently small and multi-
focal than they are large and territorial [16–18], and
magnetic resonance imaging often shows multiple areas
of restricted diffusion rather than a single, large infarc-
tion [18–20]. These patterns of injury are more consist-
ent with widespread pathology in small vessels than they
are with ischemia from large-vessel narrowing. Further-
more, while profound, large-vessel spasm can lead to
significant drops in regional cerebral blood flow (rCBF),
there is not always a clear link between perfusion and
large-vessel diameter [11, 21]. There is, however, a
strong and statistically significant correlation between
small-vessel resistance and rCBF [11].
The mechanism by which small vessels contribute to
ischemic injury is not well understood, but several hy-
potheses have been advanced. One that has received ex-
tensive attention relates to the brain’s ability to regulate
its own perfusion. Though large-caliber vessels contrib-
ute proportionally more to vascular resistance in the
brain than in other tissues [22], small cerebral arterioles
remain the primary regulators of rCBF. In the healthy
brain, decreased pressure from large artery constriction
or systemic hypotension is compensated for by dilation
of these arterioles, a process that maintains tissue per-
fusion within normal ranges. Small vessels also dilate in
response to spikes in local neuronal firing, both to de-
liver the substrates required for metabolism and also to
clear its by-products.
SAH appears to impair these homeostatic mecha-
nisms. In one study, the severity of ischemic lesions
was associated with labile blood pressure, a finding that
could be explained by an inability of the brain to regu-
late blood flow appropriately in the face of drops in
pressure [16]. Imaging studies and invasive tissue ox-
imetry have provided more direct evidence that this
autoregulatory response is absent, and there is some
suggestion that the duration of impairment is related
to subsequent DND [23, 24]. Mechanistic support for
these clinical data are provided by animal work, which
has shown that the normal physiologic dilation of both
pial and intracerebral arterioles in response to in-
creased neuronal activity is blunted temporarily after
SAH [25, 26].
As discussed below, emerging evidence indicates that
the pleiotropic signaling molecule nitric oxide (NO)
and its downstream signaling pathways play a central
role in the normal and pathological regulation of cere-
bral microvasculature.
Current treatments for vasospasm
The substantial morbidity and mortality caused by
SAH has long driven the search for effective treat-
ments. While some interventions have shown promise,
outcomes remain poor.
Hemodynamic therapy with induced hypertension and
volume expansion was first used in the 1970s, and early
series demonstrated that these therapies were effective
in as many as 85 % of patients [27, 28]. In the decades
since, they have become widely accepted interventions.
By raising systemic blood pressure and decreasing blood
viscosity, one can maintain flow in the distal vasculature
despite the greater pressure drops across spastic prox-
imal vessels, thereby preserving cerebral perfusion. It is
not a completely benign treatment, however, as up to
one third of patients suffer complications such as pul-
monary edema, congestive heart failure, or myocardial
infarction. Furthermore, high-quality evidence of im-
proved patient outcomes is lacking [27, 29].
Whereas hemodynamic therapy works by circumventing
the presumed source of ischemia, several treatments to
address the spasm itself have been tried without great suc-
cess. For example, clazosentan is an endothelin receptor A
antagonist that showed initial promise for treating DND.
In a phase 2 study, the drug reduced the incidence of
moderate or severe radiographic large-vessel spasm from
66 to 23 % [29]. Despite this impressive effect, a follow-up
phase 3 study showed no significant difference in the
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incidence of neurological deficits (21 vs. 25 %, P = 0.10) or
poor long-term outcome (29 vs. 25 %, P = 0.10) [30]. Simi-
larly, the vasodilatory calcium channel blocker nicardipine
does not appear to improve long-term outcomes; in a ran-
domized control trial, there was no significant effect of the
drug on either infarct burden (129 vs. 148 cm3, P = 0.58)
or the number of patients with poor long-term outcome
(45 vs. 44 %, P = 0.46) [30]. Interventional approaches
such as balloon angioplasty and intra-arterial vasodilator
injection have also been employed with rates of radio-
graphic improvement as high as 100 % in some series [31],
but high-quality evidence of improved long-term neuro-
logical outcomes is wanting [29].
By contrast, the calcium channel blocker nimodipine
has only modest effects on angiographic spasm, but it is
the only agent that has been repeatedly demonstrated to
have beneficial effects on outcome in multiple studies,
including randomized control trials [32–34]. A meta-
analysis concluded that the odds of a good outcome
were 1.86 times higher in patients treated with nimodi-
pine and the odds of infarction were reduced by a factor
of 0.46 [35]. The mechanism of this effect is not well
understood, but it may be related to effects on microvas-
culature or its ability to restore the local autoregulatory
increase in blood flow that occurs with neuronal activity
and which is lost in SAH [36].
Some authors have also found that HMG-CoA reduc-
tase inhibitors (statins) lower the risk of DND, with one
meta-analysis concluding that treatment lowers the
relative risk to 0.38 [37–39]. Though primarily used to
reduce cholesterol synthesis and lower the risk of car-
diovascular disease, this class of drugs is also known to
modulate the inflammatory response, inhibit platelet
activation, improve endothelial function, and upregu-
late expression of endothelial NO synthase (see below),
which may underlie this benefit. While a recent random-
ized clinical trial failed to demonstrate evidence of im-
proved outcomes as evaluated by the modified Rankin
scale (odds ratio 0.97, P = 0.803), the duration of ther-
apy was brief and detailed cognitive outcomes were not
assessed [40, 41].
Nitric oxide has multiple roles in brain physiology
NO may play an important role in mediating some of
the beneficial effects of these treatments. NO is a pleio-
tropic signaling molecule that is produced by the en-
zyme nitric oxide synthase (NOS). Three isoforms of
this protein are present in the brain and are expressed
by distinct cell types: endothelial cells (eNOS), macro-
phages and microglia (inducible NOS, iNOS), and neu-
rons and astrocytes (nNOS). As in other tissues, eNOS
is constitutively active and produces a low basal level of
NO that is important in vascular relaxation and in pre-
venting platelet activation and thrombosis [42]. nNOS
is constitutively expressed, and its activity helps to
modulate neuronal signaling. The synthesis and release
of NO by eNOS and nNOS occurs in response to nor-
mal physiological cues and together prevents vaso-
spasm and vasoconstriction [43]. The inducible
isoform, iNOS, is expressed primarily in microglia and
astrocytes in response to inflammation and ischemic in-
jury [44, 45]. The regulation of NOS synthesis, activity,
and cellular localization is complex, involving transcrip-
tional, post-transcriptional, and post-translational (e.g.,
phosphorylation) mechanisms [46].
In addition to its important intrinsic hemodynamic
role, NO modulates intracellular signaling and neuro-
transmission through a variety of mechanisms [44]. The
molecule has been found to protect against neuronal
damage and death by blocking apoptosis, ameliorating
excitotoxic injury, and inducing expression of antioxi-
dants during inflammation [44]. Yet NO can also have
toxic effects on neurons. During inflammation or excito-
toxicity, NO produced by iNOS reacts with superoxide
anions to form peroxynitrite-derived cytotoxic N2O· and
OH· radicals, strong oxidizing agents that can damage
cellular components and cause cell death [43, 47]. More
directly, NO itself can cause cellular dysfunction through
nitrosylation of serine residues on cellular proteins. It
also perpetuates inflammation through induction of cy-
clooxygenase, the products of which include several pro-
inflammatory mediators [44].
Nitric oxide mediates vasospasm in SAH
Synthesis and release of NO into the vasculature occurs
in response to normal physiological cues to induce cere-
brovascular dilation [47]. However, vasospasm after SAH
is associated with a 40 % reduction in NO elaboration by
endothelial cells (via eNOS) and neurons (via nNOS) in
the vessel adventitia [48, 49]. Moreover, oxidized heme
products released from the initial hemorrhage scavenge
free NO and elicit synthesis of endogenous eNOS inhibi-
tors, such as asymmetric dimethylarginine [48]. In line
with these findings, the normal vasodilatory response to
exogenous NO precursors is blunted in animal models
of SAH in a time course mirroring that of DND in
humans [25, 26, 49].
Spreading ischemic injury exacerbates the situation by
promoting the death of nNOS-expressing neurons. In
addition, ischemia produced by vasospasm likely induces
NO synthesis and release into the brain parenchyma
(rather than in the cerebrovasculature) by microglia
and astrocytes expressing iNOS [50]. As described
above, high levels of parenchymal NO react readily with
the superoxide anion that is produced in abundance in
response to cerebral ischemia [51]. The resulting perox-
ynitrate reacts at physiological pH to produce free
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radicals, mediators of protein, and DNA damage that
culminate in cell death.
Finally, there exist a few observations of the alteration
of NOS isoform abundance and phosphorylation state in
response to SAH [52, 53]. Of immediate relevance are
the findings of Osuka et al. that active eNOS (i.e., phos-
phorylated at Ser1177) is transiently elevated by twofold
in endothelial cells of the rat basilar artery 24 to 48 h
after induction of SAH by puncture of the anterior
cerebral artery [52]. Notably, iNOS content was detect-
able 6 h after SAH and was maximally expressed at
48 h, at which time, immunopositivity for nitrotyrosine
(NT) was noted. Elevation of iNOS and NT in the
vascular wall is indicative of nitrosative damage that
may underlie the physiological and histological changes
observed in arteries in vasospasm [52]. Therefore, sup-
pression of iNOS production may reduce ischemic
damage after SAH.
Ultrasound—observations of peripheral vascular
vasodilation and/or NO production and their potential
relationship to cerebrovascular processes
Here, we briefly review the published work motivating
our hypothesis that ultrasound (US) may reduce ische-
mic damage not through clot removal [54, 55], but
through the complementary mechanism of vasodilation.
Most studies have targeted the use of US for vasodila-
tion of peripheral tissues, measured typically with US
imaging with concurrent documentation of NO pro-
duction or its direct correlates. These publications are
summarized in Table 1. Many US protocols studied
thus far in the context of NO production have used very
low intensities (of order 0.2–1.0 W/cm2) pulsed with repe-
tition frequencies on the order of 1 kHz (when not applied
continually), across a range of US frequencies (0.02–
3.0 MHz).
Broadly speaking, US applied peripherally has been
shown to enhance blood flow within minutes of its appli-
cation in both animal [56, 57] and human [58] models,
mediated by the release of NO on time scales of seconds
in vitro [59] to minutes in vivo [56–58]. In addition, US
had longer lasting effects (measured up to 24 h [55]) on
biological mechanisms that inhibit intraparenchymal NO
production, a source of secondary injury, and enhance
intravascular NO production, a source of therapeutic
vasodilation.
Sugita et al. demonstrated a dose-dependent increase
in NO elaboration by rabbit muscle tissue in response
to US, with a maximal increase of 20 % when exposed
to US with a power of 0.48 W/cm2 [57]. This effect was
ablated by the application of L-NMMA, an NOS inhibi-
tor, indicating that the increased NO production is at
least in part due to NOS activity. Another study by
Hightower and Intaglietta showed that US can increase
blood flow in ischemic hamster skin in a manner ac-
companied by a 350 % increase in eNOS and a 60 % de-
crease iNOS [60]. However, these studies, which did
not use an US contrast agent, provided no information
on the phosphorylation state of eNOS or nNOS, and
they do not explain the mechanisms by which US stim-
ulates NOS production.
How might ultrasound affect NO production? NO
production in the vasculature is sensitive to shear stress
within the vessel walls, and ultrasound is able to gener-
ate shear stresses through two mechanisms: induction of
bulk flow within fluids, also called acoustic streaming,
and cavitation and with microstreaming around the re-
sultant microbubbles [61–63]. We note that the intensity
of ultrasound necessary to induce cavitation in brain tis-
sue is 12.7 MPa, much higher than any of the protocols
we have discussed [64], thereby favoring acoustic stream-
ing as a means by which ultrasound may enhance NO
production without causing damage to the parenchyma.
We know of only two publications relevant to the
cerebral vasculature. In rats, Alexandrov and colleagues
[65] reported significant reductions in the volume of
edematous and ischemic brain with application of a
commercially available TCD with a 2.0-MHz carrier fre-
quency, 10-mW acoustic power, and 5-KHz pulse repeti-
tion frequency. They observed significant reductions in
the volume of ischemic and edematous brain (75 vs.
22.5 mm3; 12.7 vs. 1.56 mm3, respectively) [65]. Given
the unlikely occurrence of cavitation in the brain with
these parameters [63, 64], we hypothesize this may have
occurred through US-mediated enhancement of collat-
eral flow in the volume of tissue surrounding the region
of ischemic damage, due to local US-induced vasodila-
tion of collateral blood vessels via stimulation of NO
pathways as discussed, or production of enhanced flow
via acoustic streaming. A second study by Davis et al.
[66] using primarily cultured mouse brain endothelial cells
suggests that that the reduction in infarct burden observed
by Alexandrov and colleagues [65] may be at least in part
related to elaboration of vasodilators such as adenosine
and epoxyeicosatrienoic acids. This study did not find
changes in NO levels or NOS activity, a discrepancy which
may be due to differences in US parameters and the ex-
perimental model; for example, in vitro systems are more
likely to experience US-induced cavitation, which may in-
fluence NOS activity and NO production.
Discussion
A decrease in available NO contributes significantly to
the initiation, persistence, and severity of cerebral vaso-
constriction in SAH. There exist several studies demon-
strating US-mediated induction of vasodilation via
NOS production, but in peripheral tissue not in brain
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tissue. We hypothesize that US can improve blood flow
in vasospasm by dilating spastic cerebral blood vessels
and collaterals by elevating eNOS and nNOS activity
via induction of shear stress in the vessel wall. We fur-
ther hypothesize that US can suppress expression of
iNOS, thereby limiting neurotoxicity.
If ultrasound can maintain or increase NOS produc-
tion in an ischemic brain, we anticipate that extant MRI-
guided therapeutic ultrasound systems could find use for
the treatment of cerebral vasospasm via three focusing
strategies. One would target ultrasound to the major
cerebral arteries in vasospasm in a focal manner. A sec-
ond focusing strategy would target generally large vol-
umes of brain tissue containing secondary arteries in
vasospasm by defocusing the nominally therapeutic
ultrasound. The goal of these two strategies is to directly
reverse vasospasm in these major and minor cerebral ar-
teries. A third strategy would target collateral blood ves-
sels that are available to perfuse brain tissue downstream
from the spastic vasculature.
Fortunately, several studies support the idea that
existing MRI-guided ultrasound systems could usefully
treat ischemia due to vasospasm. For example, Sugita
and colleagues used ultrasound consistent with existing
MRI-guided ultrasound therapy systems (here, 490 KHz,
approximately 0.2–0.5 W/cm2, useful for transcranial ap-
plication) to demonstrate enhanced production of NO in
vivo that scaled with the intensity of ultrasound [57]. Also,
Table 1 Published literature regarding ultrasound-mediated vasodilation





• 2.5 MHz, continuous wave
• 8 W/cm2
• 0.5 MPa
• 20-min application to skin
• Microcirculation transiently decreased at 0.5 h
but increased at 24 h
• iNOS decreased at 2 h
• eNOS increased at 24 h






• 1.4 W/cm2 SPTA
• Pulsed at 300
• 5-, 30-, 60-, and 90-min transcutaneous
applications
• 9 % increase in the luminal area after 30 s of US,
19 % increase after 3 min
• Return to baseline 90 min after cessation of US






• 0.128 or 0.010 W/cm2
• Transcranial application 1-h exposure
after acute MCA occlusion
• Decrease in cerebral edema and infarction
volume at 0.010 W/cm2
• No effect at 0.128 W/cm2
Suguta et al. 2000 [57] In vivo
Rabbit thigh adductor
muscle
• 490 kHz, continuous wave
• 0.25–1.7 W/cm2 SATA
• 0.35–0.48 W/cm2 SPTA
• Direct application
• NO production increased by 20 %
• NO elaboration increases within 1 min of US
application and decreases within 1 min of cessation
• Effect partially ablated by NOS inhibitor L-NMMA








• Tissue perfusion improves over 60-min US application
• NOS activity increased; effect blocked by NOS
inhibitor L-NAME




• 0.025–0.125 W/cm2, continuous wave
• 0.25 W/cm2 pulsed 10 % duty cycle
(10 Hz, 270 cycles per burst) SPTP
• Direct exposure of variable duration,
10 s to 30 min
• Significant increase in NO elaboration and eNOS activity
• Effect seen with 10-s application, increased up to
1-min application
• Pulsed 10 % duty cycle yielded greater NO
than continuous wave
Iida et al. 2006 [58] In vivo
Human brachial artery
• 29 kHz
• 1.4 W/cm2 (0.12 W/cm2 ISATA)
• Pulsed at 25 Hz, 30 % duty cycle
• Transcutaneous application for 1, 2, 3,
or 5 min
• Artery diameter increased after 2 min of US
• Returned to baseline 21 min after cessation
• Nonresponders were older




• 1 MHz 25 % pulsed
• 0.5, 1.0, 1.6, and 2.0 W/cm2 ISATA
(attenuated to 0.68 W/cm2)
• 10 min, once daily for 6 days
• Increased extracellular matrix production in response
to US
• Culture medium NO increased approximately 50 %
at 1.6 W/cm2
• Culture medium Ca2+ increased by approximately
20 % at 1.0, 1.6, and 2.0 W/cm2




• 0.35, 0.55, 0.90, and 1.30 MPa
• Pulsed at 50 Hz
• Increased production of various vasodilator molecules
(e.g., adenosine, metabolites of arachidonic acid) in
response to US
• NO levels undetectable
• eNOS phosphorylation unchanged
HUVEC human umbilical vein endothelial cells, BAEC bovine aortic endothelial cells, MCA middle cerebral artery, US ultrasound, SATA spatial average-temporal average,
SPTA spatial peak-temporal average, ISATA spatial average-temporal average intensity
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Hightower and Intaglietta also used an ultrasound proto-
col capable of transcranial delivery via extant MRI-guided
ultrasound systems (2.95 MHz, 1 W/cm2, 5 KHz pulse
repetition frequency) [60]. These are close to what existing
MRI-guided therapeutic ultrasound systems can deploy:
the Insightec system deploys ultrasound at 220 and
660 kHz. The Philips and SSI machines deploy ultrasound
at 1 MHz. And, interestingly, the likely most efficacious
ultrasound protocols should conform to FDA-approved
guidelines for diagnostic ultrasound, given the low inten-
sities necessary to create peripheral vasodilation, thereby
reducing the regulatory barrier to clinical trials of MRI-
guided therapeutic ultrasound to treat vasospasm in SAH.
If effective in manipulating CBF, this technology may
also prove to have uses beyond DND after SAH. In is-
chemic stroke, for example, neuronal death begins mi-
nutes after the onset of ischemia, but tissue injury and
cell loss progress over hours and even days in the pen-
umbra [43], providing a crucial window for intervention.
More broadly, perturbations in CBF feature prominently
in neurological conditions not traditionally thought of as
vascular in nature, such as migraine [67] and Alzhei-
mer’s disease [68]. Should US prove effective in manipu-
lating CBF and mitigating ischemia after SAH, perhaps it
may find even broader indications.
Caution must be undertaken with any new therapy,
however, and US is no different. Indeed, there is some
evidence that US with a combination of high intensity
and low frequency could be harmful [69]. Moreover,
some have described vasoconstriction in response to
lower intensities of US co-administered with acoustic
contrast agents [70], which would obviously be coun-
terproductive in patients with vasospasm. Clearly, sig-
nificant research and development with an eye towards
safety and efficacy are required before application of
these ideas to patients.
Conclusion
Delayed neurological deficits after subarachnoid hemo-
rrhage remain a major cause of long-term morbidity and
mortality, and the clinical tools available to treat the condi-
tion are fairly limited in efficacy. There exists a large body
of literature implicating disordered NO signaling as a
cause of this clinical problem. We hypothesize that appli-
cation of US may induce cerebral vasodilation and restore
blood flow to ischemic brain via increased elaboration of
NO. In the future, MRI-guided therapeutic US systems
may one day find their way through clinical trials and into
regular clinical practice, most obviously as a treatment for
cerebral vasospasm but also, possibly, for other cerebro-
vascular diseases.
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